Syngene International Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services  

30th May, 2018, Bengaluru, India and Boston, USA 

Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery.

Under the terms of the agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partners.

Kavitha Iyer Rodrigues, Founder-CEO, Zumutor Biologics said, “Zumutor will use its proprietary antibody display platform to enhance Syngene’s discovery programmes.  Our antibody engineering expertise and experience enables us to optimize any lead to evolve into a best-in-class differentiated molecule”

Commenting on the collaboration, Dr. Manoj Nerurkar, Chief Operating Officer, Syngene International, said, ” Syngene has been a pioneer in discovery research and we see Discovery Biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients”

About Zumutor Biologics: Zumutor Biologics Inc. is a leading Immuno Oncology Company focusing on novel monoclonal antibody therapeutics against innate immunity targets. Zumutor’s high diversity human antibody libraries serve as powerhouse for developing novel monoclonal antibody therapeutics targeting various immuno oncology pathways. Their product pipeline constitutes unique immuno-oncotherapeutics that target innate immunity and regulate tumor micro environment. Zumutor’s lead candidate in Prostate cancer revealed significant tumor reduction, when applied alone and in combination with check point inhibitor in mouse efficacy study. For more details, visit

About Syngene: Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is one of the largest and fastest growing Contract Research Organizations in the world. The Company is committed to creating strong customer impact through its cutting edge scientific capabilities and state-of-the art research and manufacturing infrastructure. It provides integrated discovery and development services across multiple technology platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides under an environment of high regulatory compliance and safety. Syngene serves over 300 clients in the pharma, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries, including 8 of the top 10 global pharma companies. Its innovation driven culture and a strong team of over 3500 scientists, help R&D focused organizations improve productivity and performance while shortening the development time and cost. For more details or to see how Syngene can support your innovation, visit


For further information, please reach out to:


Syngene International

Investor Contact

Kavitha Iyer Rodrigues

Cell (India): +91- 9845597393

Cell (US): +1(267) 370 6267

Chanderlekha Nayar      

Ph: +91 80 6775 8821

Cell: +91 7259192001




Media Contact

Kavitha Iyer Rodrigues

Cell (India): +91- 9845597393

Cell (US): +1(267) 370 6267

Sandeep Nair

Ph: +91 80 6775 8775

Cell: +91 88843 67776